semaglutide/NNC0480-0389 (NN9389) / Novo Nordisk - LARVOL DELTA

CO-ADMINISTERED SEMAGLUTIDE AND GLUCOSE-DEPENDENT INSULINOTROPIC PEPTIDE RECEPTOR AGONIST COMPARED WITH MONOTHERAPIES AND PLACEBO IN PEOPLE WITH TYPE 2 DIABETES: A RANDOMISED, DOSE-FINDING, PHASE 2 TRIAL (ATTD 2024) - P2 | "Background and Aims: This phase 2 trial (NCT05144984) was designed to determine the dose ratio, efficacy and safety of a proposed fixed-dose combination of the glucagon-like peptide-1 analogue, semaglutide, and the glucose-dependent insulinotropic peptide receptor agonist (GIPRA), NNC0480-0389. This was a randomised, double-blind, placebo-controlled, dose-finding trial including adults with type 2 diabetes (HbA1c 7–10%) treated with diet and exercise with/without metformin... Semaglutide co-administered with GIPRA was superior to placebo and GIPRA monotherapy, but did not improve glycaemic control more than semaglutide monotherapy, in this population. No new safety concerns were identified with co-administration or GIPRA monotherapy compared with semaglutide monotherapy.Funding: Funded by Novo Nordisk A/S."

Clinical • P2 data • Diabetes • Gastrointestinal Disorder • Metabolic Disorders • Type 2 Diabetes Mellitus

A Research Study Looking at How Well a Combination of the Medicines Semaglutide and NNC0480-0389 Works in People With Type 2 Diabetes (clinicaltrials.gov) - P2 | N=500 | Completed | Sponsor: Novo Nordisk A/S | Active, not recruiting ➔ Completed

Combination therapy • Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus • APOB • CRP